HER-2在骨肉瘤中蛋白表达、基因扩增及临床意义研究  

The expression of HER-2 protein,gene amplification and clinical significance in osteosarcoma

作　　者：杜振广[1] 徐绍年[1] 李福生[1] 王亮[1] 黄海[1] 翟墨[1] 

机构地区：[1]辽宁省人民医院骨四科,辽宁沈阳110016

出　　处：《临床军医杂志》2017年第4期363-365,共3页Clinical Journal of Medical Officers

摘　　要：目的探讨骨肉瘤中人类表皮生长因子受体-2(HER-2)的蛋白表达、基因扩增及其临床意义。方法收集2002年1月至2015年6月辽宁省人民医院的51例骨肉瘤及20例骨软骨瘤存档蜡块,采用免疫组化法检测其HER-2蛋白表达情况;采用免疫荧光原位杂交技术(FISH)检测HER-2基因扩增情况。结果在骨肉瘤及骨软骨瘤中HER-2蛋白的阳性表达率分别为64.7%及0;HER-2基因扩增的阳性率分别为58.8%、10.0%;组间比较,差异均有统计学意义(P<0.01)。结论骨肉瘤中HER-2基因扩增及蛋白表达均高于骨软骨瘤,可作为其分子靶向治疗的靶点。Objective To investigate the expression of HER-2 protein,gent amplification and clinical significances in osteosarcoma. Methods Using immunohistochemical SP method and in situ chemical hybridization（FISH） to detect the expression of HER-2 protein, gene amplification in 51 cases of osteosarcoma and 20 cases of osteochondroma. Results The positive rate of HER-2 expression in osteosarcoma and osteochondroma were 64. 7%, 0, respectively. The positive rate of HER-2 gene amplification were 58. 8%, 10. 0%, respectively. There were significant differences between osteosarcoma and osteochondroma in the expression and amplification of HER-2 （P 〈 0. 01 ）. Conclusion HER-2 gene amplification and protein expression in osteosarcoma are higher than those of osteochondroma,which can be used as a target for molecular targeted therapy.

关 键 词：骨肉瘤 人类表皮生长因子受体-2 免疫组织化学 荧光原位杂交 

分 类 号：R734.202[医药卫生—肿瘤]